Paxlovid

HHS has announced that it will work with pharmacies, insurers and health systems to make sure that all Americans ...

MARCH 5, 2024

The FDA announced a revision to the emergency use authorization for Paxlovid: Product manufactured and labeled in ...

FEBRUARY 21, 2024

HHS announced a plan to smooth the transition to traditional ordering, distribution and payment for COVID-19 ...

DECEMBER 24, 2023

The FDA approved the oral antiviral Paxlovid to treat mild to moderate COVID-19 in adults who are at high risk for ...

MAY 25, 2023

Available data support the safety and effectiveness of Paxlovid to treat mild to moderate COVID-19 in adults who ...

MARCH 17, 2023

The return of COVID-19 symptoms or a positive test after treatment with nirmatrelvir+ritonavir (Paxlovid, Pfizer) ...

SEPTEMBER 2, 2022

When FDA first issued the EUA for Paxlovid, it established a 12-month product shelf-life, but some packages were ...

JULY 26, 2022

The president will continue to work, but will remain isolated in the White House residence.

JULY 21, 2022

The FDA is hoping that revising the EUA for Paxlovd will improve access to the medication for some patients at high ...

JULY 7, 2022

Paxlovid reduces hospitalizations and deaths from COVID-19, so clinicians should not avoid prescribing it for mild ...

JUNE 2, 2022

The new oral COVID-19 drug has special dispensing requirements for those with moderate renal impairment.

JANUARY 6, 2022